

TARGET POPULATION

Asymptomatic men and women of all ages

EXCLUSIONS

Men and women with signs or symptoms suggesting colorectal cancer screening (CRC)

RECOMMENDATIONS

RISK ASSESSMENT

- ✓ Assess risk for colorectal cancer (CRC) for all men and women to determine when to start screening, the appropriate screening test and frequency
- X DO NOT wait for patient to turn 50 years of age to assess risk for CRC
- ✓ Assess for indicators of increased risk including family and/or personal history of colorectal cancer, colonic adenomas or inflammatory bowel disease, and high risk CRC conditions, i.e., Lynch syndrome, familial adenoma polyposis

AVERAGE RISK POPULATION

FECAL IMMUNOCHEMICAL TEST (FIT)

50 TO 74 YEARS OF AGE

- ✓ Screening is recommended with the Fecal Immunochemical Test (FIT)
- ✓ Screen with FIT every one to two years
- ✓ If the FIT result is positive, promptly refer for a colonoscopy. Use local CRC screening program (see [Appendix A](#)) or endoscopist, depending on available resources
- ✓ Wait 10 years after a normal colonoscopy to start or re-start screening with FIT. If the quality of the colonoscopy was uncertain, start or re-start screening with FIT five years after the colonoscopy

PRACTICE POINT

*FIT is the recommended screening test for average risk men and women between 50 and 74 years of age
Screen with FIT every one to two years*

75 YEARS OF AGE AND OLDER

- X As a general practice, DO NOT screen asymptomatic patients with a life expectancy of less than 10 years and no family or personal history of colorectal neoplasia
- ✓ Discuss the risks and benefits of screening with the patient. The decision to screen should be individualized, based on informed patient preference, and between the patient and his/her physician

WHEN NOT TO USE FIT

- X DO NOT use as a diagnostic test for CRC in SYMPTOMATIC patients (e.g., reported bloody stools or recent change in bowel habit)
- X DO NOT use to determine or exclude a cause for anemia
- X DO NOT use when an average risk patient has had a high quality colonoscopy within the past 10 years
- X DO NOT use as a CRC screening test when the patient has an acute gastrointestinal (GI) condition and/or where bleeding is occurring or highly likely:
 - Inflammatory bowel disease
 - Acute gastroenteritis or *C. difficile* colitis
 - Actively bleeding hemorrhoids or anal fissure

OTHER SCREENING TESTS

The FIT is the recommended method of screening for the average risk population. [Appendix B](#) summarizes the evidence for other CRC screening tests, e.g., colonoscopy, flexible sigmoidoscopy, CT colonography, and others. Expertise and availability varies across the province.

INCREASED RISK POPULATIONS

Family history of colorectal cancer and/or high risk colonic adenomas are warning signs of increased risk (see Risk Assessment section for definition of high risk adenomas). Use clinical judgment.

One first degree relative > 60 years at diagnosis of colorectal cancer and/or high risk adenomas

- ✓ Screen with FIT every one to two years starting at age 40
- ✓ If the FIT result is positive, promptly refer for a colonoscopy. Use local CRC screening program (see [Appendix A](#)) or endoscopist, depending on available resources

One first degree relative ≤ 60 years at diagnosis of colorectal cancer and/or high risk adenomas or two or more affected relatives

- ✓ Refer for consideration of colonoscopy at age 40, or 10 years prior to the index case, whichever is earliest. Use local CRC screening program (see [Appendix A](#)) or endoscopist

- ✓ Assist patient with adherence to follow-up as recommended by local CRC screening program (see [Appendix A](#)) or endoscopist

Personal history of colorectal cancer, colonic adenomas or inflammatory bowel disease (i.e., ulcerative colitis or Crohn's Colitis)

- ✓ Assist patient with ongoing follow-up by colonoscopy as recommended by local CRC screening program (see [Appendix A](#)) or endoscopist
- ✓ Use provincial Post Polypectomy Surveillance Guidelines available at: www.albertahealthservices.ca/1751asp
- ? Be aware that not all polyps are considered high risk and require surveillance, e.g., small, single, hyperplastic polyps found in the distal colon

High risk CRC conditions include: Lynch syndrome or familial adenomatous polyposis (FAP)

- ✓ Ensure patient has an established relationship with the local CRC screening program (see [Appendix A](#)) or an endoscopist for on-going care and monitoring

PRACTICE POINT

Lynch syndrome (HNPCC) is identified by personal and family history of multiple cancers, including endometrial, gastric, ovarian, hepatobiliary, urinary tract

EVIDENCE-BASED IMPLEMENTATION CONSIDERATIONS

CRC screening is an important preventive health activity in which education and outreach are key components. Efforts to reduce CRC should include strategies that increase the number of individuals who present for screening. Health care providers can use opportunistic (screening when the patient presents for other reasons) and outreach (contacting patients who are due for screening interventions to promote screening. Relying on routine checkup appointments will likely miss many patients. Patient contact for any reason can be used to discuss CRC screening. Some program results indicate that the strongest stimulus for men and women to participate in CRC screening is the recommendation from a health care provider.

- ✓ Use preventive screening checklists, opportunistic screening, and outreach to increase the likelihood of engaging men and women to participate in CRC screening

BACKGROUND

RISK

CRC is the second most common cause of cancer death for males and the third most common cause of cancer death for females.¹ The probability of developing CRC increases with age and varies with sex. In Alberta, approximately one in 13 men and one in 16 women will develop invasive CRC within their lifetime.² Males have a greater chance of dying from CRC than females, i.e., 1/32 males and 1/36 females will die of invasive CRC.² According to Alberta statistics, CRC mortality rates decreased

over the period 1990 to 2010, for both males and females.² Declining rates may be attributed to screening's effect on early detection and management. CRC can be prevented by the detection and removal of precancerous polyps.

AGE

The incidence of CRC increases with age. Rates are low until about age 40, with the incidence increasing in older age groups.² In Alberta, the probability of developing cancer at ages 30-40 years is one in 1,613 for males and one in 1,365 for females.² For those 50-60 years of age, the rate is one in 450 for males and one in 410 for females.² According to the United States Preventive Services Task Force, more than 80% of diagnosed cases of CRC occur in those older than 55 years.³ (See [Table 1](#)). For the majority of those with CRC, age is the only risk factor.

Age Group (Years)	Males	Females
Lifetime Risk (all ages)	1 in 13	1 in 16
0-20	Less than 1 in 10,000	Less than 1 in 10,000
20-30	1 in 5,428	1 in 4,506
30-40	1 in 1,613	1 in 1,355
40-50	1 in 450	1 in 410
50-60	1 in 161	1 in 158
60-70	1 in 77	1 in 77
70-80	1 in 45	1 in 46
80+	1 in 28	1 in 25

*Table 1: Probability of Developing Colorectal Cancer by Age and Sex, Alberta 2006 – 2010
Reproduced with permission from Alberta Cancer Registry, Alberta Health¹*

FAMILY HISTORY

Next to age, family history is the most common risk factor for CRC.⁴ Risk of CRC increases as the number of affected relatives increases and the younger the age of the relative at diagnosis.⁵⁻⁷ For example, having multiple family members with CRC prior to age 60 carries a higher risk than one family member with CRC at an advanced age. According to one meta-analysis, a population lifetime risk for a 50 year old was 1.8% but increased to 3.4% with at least one affected relative and 6.9% with two or more affected relatives.⁶

LYNCH SYNDROME

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), accounts for 1% to 3% of all colorectal cancers.^{8,9} It carries a lifetime risk for CRC estimated at 50-80%, and is higher for men than for women.⁹⁻¹⁰ Besides being associated with CRC, Lynch syndrome carries a 40-60% lifetime risk of endometrial cancer.¹⁰ To a lesser degree (<19%), other cancers associated with Lynch syndrome include: gastric (11-19%), ovarian (9-12%), hepatobiliary (2-7%), upper urinary tract (4-5%), pancreatic (3-4%), small bowel (1-4%), and CNS – glioblastoma (1-3%).¹⁰

FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

FAP accounts for up to 1% of all CRC.¹¹ Almost all men and women with FAP will develop CRC if they are not identified and treated at an early stage.¹¹

INFLAMMATORY BOWEL DISEASE (IBD)

IBD is associated with increased risk for CRC. For ulcerative colitis, the probability of developing CRC after 10 years of diagnosis is estimated at 2%, reaching 8% after 20 years and 18% after 30 years.¹²

DIABETES MELLITUS

A recent meta-analysis found that diabetes is associated with an increased risk of colon cancer (relative risk 1.38 for both men and women) and rectal cancer (relative risk 1.20 for men).¹³ The association remained when the authors controlled for smoking and obesity, or for smoking, obesity and physical exercise.

OBESITY

Body mass index (BMI) and waist circumference (WC) are positively associated with risk for CRC. In one meta-analysis the relative risks for the obese versus normal category of BMI were 1.334 and the relative risk for the highest versus lowest category of waist circumference were 1.455.¹⁴ There was less heterogeneity among studies of waist circumference.

LIFESTYLE

Physical activity: There is consistent evidence supporting an inverse relationship between physical activity and risk of CRC. The overall relative risk for those who are physically active is 0.76 with the relative risk at 0.76 for men and 0.79 for women.¹⁵ The impact of physical activity in reducing CRC risk is supported by biological mechanisms, including: “decreased inflammation, reduced intestinal transit time, decreased insulin-like growth factor levels, reduced hyperinsulinemia and modulated immune function.”¹⁵

Alcohol consumption: There is a strong link between alcohol consumption and CRC evident for those who drink two or more alcoholic beverages a day. A higher relative risk is observed when comparing moderate drinkers (two to three drinks a day) to heavy drinkers (four or more drinks a day), and there may be a stronger risk for men.¹⁶

Smoking: Smoking is strongly associated with increased risk for colorectal cancer and mortality, including a significant dose-response relationship.¹⁷

Diet: There is evidence that higher intake of processed and red meat are positively associated with CRC.¹⁸

RECOMMENDATIONS

RISK ASSESSMENT

To determine the appropriate approach to CRC screening, it is important to assess an individual's risk considering age, family history, personal history and presence of high risk conditions. These factors will determine when screening should be initiated, and the appropriate tests and frequency. Individuals considered at increased risk include:

- Family history of CRC or high risk colonic adenomas in a first degree relative or two or more affected relatives.
 - A **high risk colonic adenoma** is defined as having one or more of the following:
 - Size greater or equal to 1 cm
 - Villous elements
 - High grade dysplasia
 - More than three adenomas found at one colonoscopy.

For further information, please see Post Polypectomy Surveillance Guidelines:

www.albertahealthservices.ca/1751.asp

- Personal history of CRC, colonic adenomas, or inflammatory bowel disease (i.e., ulcerative colitis or Crohn's colitis)
- High risk conditions, such as Lynch syndrome or familial adenomatous polyposis

Based on risk stratification, follow the recommendations for either the [Average Risk Population](#) or [Increased Risk Population](#).

AVERAGE RISK POPULATION

The average risk population includes men and women ages 50 to 74 years with no signs or symptoms suggesting CRC, and the absence of family history, personal history or other high risk CRC conditions as described in the section on [Increased Risk Population](#).

Screening test: The Fecal Immunochemical Test (FIT) is the recommended method for screening average risk men and women. This stool-based test relies on the detection of blood from adenomas or carcinomas.³ The FIT uses an antibody against human globin – the protein part of hemoglobin.¹⁹ In comparison to the guaiac fecal occult blood test (gFOBT), the FIT has higher sensitivity, specificity and test adherences rates.¹⁹ A systematic review of randomized control trials (RCTs) comparing diagnostic accuracy of the gFOBT versus FIT, found better performance by the FIT, with positivity rates and sensitivities both higher than gFOBT.¹⁹ One RCT reported the FIT to be twice as likely to find colorectal cancers and five times more likely to find advanced polyps.²⁰ The FIT does not have dietary restrictions and thus is not subject to false negative results in the presence of Vitamin C supplements.²⁰

RCTs have studied the likelihood of completing screening with FIT as compared to the gFOBT^{20,21} and colonoscopy.²¹ In both cases, compliance with the FIT is superior, i.e., 24.6% for colonoscopy versus 34.2% for FIT;²¹ and 12% more favorable participation rate for FIT vs. gFOBT.²⁰

There are no RCTs available evaluating the outcomes of FIT screening to mortality from CRC. A 2007 Cochrane review²² pooling RCT results of the gFOBT found that a CRC screening program with biennial gFOBT can lead to a 16% reduction in CRC mortality after 12 to 18 years of periodic screening and a 25% CRC mortality reduction for those attending at least one round of gFOBT screening. Given the increased test performance and adherence rates for FIT compared to the gFOBT, the effect of screening with the FIT is anticipated to produce even better outcomes.

Other guidelines support FIT over gFOBT because FIT has both superior test characteristics and adherence rates for the detection of CRC.²³⁻²⁵

Screening interval: One and two year screening intervals are recommended in other CRC screening guidelines and are primarily based on modelling studies.^{2,20,22} There is, however, strong evidence to support that the effectiveness of screening, for all screening modalities, will decrease substantially if adherence to the screening regimen declines.^{3,26} This committee recommends every one to two years. This allows family physicians some flexibility to realistically meet this standard.

Screening following a normal colonoscopy: For men and women with a normal colonoscopy result, wait 10 years to start or re-start screening with FIT. This recommendation is based on the recommendations from other guidelines^{24,27} and observational and case control studies suggesting that patients with colonoscopy have reduced CRC incidence or mortality for duration of effect of 10 years or more.²⁷ This recommendation is valid for high quality colonoscopy only. The quality of the colonoscopy depends on its completeness (reaching and inspecting the cecum), the quality of bowel preparation, and the degree of attention paid to mucosal details during the examination.

Positive FIT results: All men and women with a positive FIT result should be referred promptly for a colonoscopy. A repeat FIT test, just to be certain, is not recommended. One cancer is detected for every 20 positive FITs.²¹

INCREASED RISK POPULATION

Family history: Mortality reduction studies directed at screening persons with a family history of CRC or adenomatous polyps are not yet available. However, we do know that family history is the second most common risk factor for CRC after age. As stated above, this risk increases as the number of affected relatives increases and the younger the age of the relative at diagnosis. The evidence for a precise cut-off age is not strong so clinical judgment is called for.

A first degree relative or two or more affected relatives with CRC or adenomatous polyps are warning signs of increased risk. Studies are increasingly showing that first degree relatives of CRC patients had a risk of CRC at age 40 that was similar to the risk of CRC in average risk patients at the age of 50.⁶

Individuals with a first degree relative \leq 60 years at diagnosis or two or more affected relatives should be referred for consideration of colonoscopy at age 40 or 10 years before the index case, whichever comes first. Colonoscopy is the recommended screening modality as it affords opportunity for therapeutic intervention and biopsy.⁴ Family history of a first degree relative > 60 years at

diagnosis makes very little contribution to risk. A recent RCT illustrates FIT used for CRC screening (annual FIT for 3 years) detected all CRCs and was equivalent to colonoscopy for detecting advanced neoplasia in first-degree relatives of patients with CRC.²⁸ Therefore screening with FIT starting at age 40 is recommended.

In certain cases, patient anxiety and “need to know” may influence a referral.

Personal history: For individuals with a personal history of CRC, colonic adenomatous polyps or inflammatory bowel disease, regular surveillance colonoscopy is required. The recommended surveillance interval will depend on the number, type and size of colonic adenomas. Post-polypectomy surveillance recommendations are best made by the program or endoscopist that performed the colonoscopy, upon review of the pathology report. Provincial Post Polypectomy Surveillance guidelines are available at: www.albertahealthservices.ca/1751.asp. Not all polyps require surveillance. For example, no follow up is required for small, single, hyperplastic polyps found in the distal colon. A personal history of ulcerative colitis or Crohn’s colitis also necessitates an on-going relationship with a specialist for surveillance

High risk conditions for CRC: It is important to identify individuals with high risk conditions for developing CRC, and ensure the patient has an established relationship with an endoscopist or surveillance program. These conditions include: Lynch syndrome (HNPCC) and familial adenomatous polyposis (FAP). Consider Lynch syndrome in those with a personal or family history of multiple cancers, some of which include colorectal, endometrial, gastric, ovarian, hepatobiliary, upper urinary tract, pancreatic, small bowel and CNS – glioblastoma.⁹ Consider FAP in those presenting with multiple colon polyps at young age.

CRC SCREENING (GREATER THAN 75 YEARS OF AGE)

CRC SCREENING ON ASYMPTOMATIC PATIENTS WITH A LIFE EXPECTANCY OF LESS THAN 10 YEARS AND NO FAMILY OR PERSONAL HISTORY OF COLORECTAL NEOPLASIA

CRC screening and surveillance testing may not be appropriate for individuals greater than 75 years old when risk is greater than benefit. The risk from the colonoscopy procedure increases for patients of older ages and especially with comorbidities. In addition, patients greater than 75 years of age are more likely to bleed, have a positive FIT and require a colonoscopy follow-up.

The decision to screen should be based on individual assessment of the risk/benefit ratio of colorectal cancer screening or surveillance for each patient. This includes results of previous screening tests, family history, any possible risks from the test, life expectancy and patient preferences. This risk/benefit ratio of screening should be understood by the patient and the decision to screen is between the patient and provider.^{2,29-31}

REFERENCES

1. Cancer Surveillance. 2010 report on cancer statistics in Alberta: Colorectal cancer [Internet]. Edmonton, AB: Cancer Care, Alberta Health Services; 2012. Available from: <http://www.albertahealthservices.ca/poph/hi-poph-surv-cancer-colorectal-2010.pdf>

2. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008 Nov 4;149(9):627–37.
3. Burt RW. Colon cancer screening. *Gastroenterology.* 2000 Sep;119(3):837–53.
4. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut.* 2010 May;59(5):666–89.
5. Butterworth AS, Higgins JPT, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. *Eur J Cancer.* 2006 Jan;42(2):216–27.
6. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. *N Engl J Med.* 1994 Dec 22;331(25):1669–74.
7. Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut.* 2013 Jun;62(6):812–23.
8. Weissman SM, Bellcross C, Bittner CC, Freivogel ME, Haidle JL, Kaurah P, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome—a review. *J Genet Couns.* 2011 Feb;20(1):5–19.
9. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. *Gastroenterology.* 2010 Jun;138(6):2044–58.
10. Vasen HFA, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). *Gut.* 2008 May;57(5):704–13.
11. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut.* 2001 Apr;48(4):526–35.
12. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *Am J Gastroenterol.* 2011 Nov;106(11):1911–1921; quiz 1922.
13. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLoS ONE.* 2013;8(1):e53916.
14. Wolin KY, Yan Y, Colditz GA, Lee I-M. Physical activity and colon cancer prevention: a meta-analysis. *Br J Cancer.* 2009 Feb 24;100(4):611–6.
15. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol.* 2011 Sep;22(9):1958–72.
16. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA.* 2008 Dec 17;300(23):2765–78.
17. Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. *Nutr Clin Pract.* 2012 Oct;27(5):613–23.
18. Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. *Can J Gastroenterol.* 2012 Mar;26(3):131–47.

19. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology*. 2008 Jul;135(1):82–90.
20. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology*. 2008 May;134(5):1570–95.
21. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanás Á, et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. *New England Journal of Medicine*. 2012;366(8):697–706.
22. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol*. 2009 Mar;104(3):739–50.
23. Leddin DJ, Enns R, Hilsden R, Plourde V, Rabeneck L, Sadowski DC, et al. Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010. *Can J Gastroenterol*. 2010 Dec;24(12):705–14.
24. European Commission, Segnan N, Patnick J, Von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis - first edition. [Internet]. Luxembourg: Publications Office of the European Union; 2011 Feb. Available from: <http://bookshop.europa.eu/en/european-guidelines-for-quality-assurance-in-colorectal-cancer-screening-and-diagnosis-pbND3210390/>
25. Coombs A, Jones-McLean E, Le-Petit C, Flanagan W, White K, Berthelot J-M, et al. Technical Report for the National Committee on Colorectal Cancer Screening [Internet]. 2002 May. Available from: <http://www.phac-aspc.gc.ca/publicat/ncccs-cndcc/techrep-eng.php>
26. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. 2012 Sep;143(3):844–57.
27. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med*. 2012 Jun 21;366(25):2345–57.
28. Quintero E, Carrillo M, Gimeno-García A, Hernández-Guerra M, Nicolás-Pérez D, Alonso-Abreu I. Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening. *Gastroenterology* 2014;147:1021–1030
29. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US multi-society task force on colorectal cancer. *Gastroenterology*. 2012 Sep;143(3):844-57.
30. Qaseem A, Denberg TD, Hopkins RH, Jr, Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: A guidance statement from the American College of Physicians. *Ann Intern Med*. 2012 Mar 6;156(5):378-86.
31. Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, et al. Adverse events after outpatient colonoscopy in the medicare population. *Ann Intern Med*. 2009 Jun 16;150(12):849,57, W152.

32. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet*. 2010 May 8;375(9726):1624–33.
33. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. *J Natl Cancer Inst*. 2011 Sep 7;103(17):1310–22.
34. Hoff G, Grotmol T, Skovlund E, Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. *BMJ*. 2009;338:b1846.
35. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of Flexible Sigmoidoscopy-Based Screening on Incidence and Mortality of Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS Med*. 2012 Dec 4;9(12):e1001352.
36. Brink D, Barlow J, Bush K, Chaudhary N, Fareed M, Hayes R, et al. Colorectal Cancer Screening. Bloomington (MN): Institute for Clinical Systems Improvement; 2012 May.
37. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013 [Internet]. Toronto, ON: Canadian Cancer Society; 2013. Available from: <http://www.cancer.ca/~media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf>
38. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. *Clin Gastroenterol Hepatol*. 2009 Jul;7(7):770–775; quiz 711.
39. Lakoff J, Paszat LF, Saskin R, Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. *Clin Gastroenterol Hepatol*. 2008 Oct;6(10):1117–1121; quiz 1064.
40. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. *JAMA*. 2006 May 24;295(20):2366–73.
41. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. *J Clin Oncol*. 2011 Oct 1;29(28):3761–7.
42. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. *Ann Intern Med*. 2011 Jan 4;154(1):22–30.
43. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of Colonoscopy and Death From Colorectal Cancer. *Ann Intern Med*. 2009 Jan 6;150(1):1–8.
44. Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. *Arch Intern Med*. 1995 Sep 11;155(16):1741–8.
45. Rosman AS, Korsten MA. Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy. *Am J Med*. 2007 Mar;120(3):203–210.e4.
46. Sosna J, Sella T, Sy O, Lavin PT, Eliahou R, Fraifeld S, et al. Critical analysis of the performance of double-contrast barium enema for detecting colorectal polyps > or = 6 mm in the era of CT colonography. *AJR Am J Roentgenol*. 2008 Feb;190(2):374–85.
47. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? *Clin Chem*. 2001 Apr;47(4):624–30.

48. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. *Eur J Cancer*. 2003 Apr;39(6):718–27.
49. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol*. 2006 Nov 20;24(33):5313–27.
50. Palmqvist R, Engarås B, Lindmark G, Hallmans G, Tavelin B, Nilsson O, et al. Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study. *Dis Colon Rectum*. 2003 Nov;46(11):1538–44.

SUGGESTED CITATION

Toward Optimized Practice (TOP) Working Group for Colorectal Cancer Screening. 2013 Nov. Colorectal cancer screening: clinical practice guideline. Edmonton, AB: Toward Optimized Practice. Available from: <http://www.topalbertadoctors.org>

For more information see www.topalbertadoctors.org

GUIDELINE COMMITTEE

The committee consisted of representatives of family medicine, internal medicine, gastroenterology, general surgery and diagnostic radiology.

2008

Revised – November 2013

Minor Revision – June 2015

APPENDIX A

CRC SCREENING PROGRAMS

EDMONTON ZONE

SCOPE Program: Edmonton AB T5K 0C0

Phone 780.735.3235

Fax 780.735.1061

Email scope@albertahealthservices.ca

Website <http://www.albertahealthservices.ca/services.asp?pid=saf&rid=1092770>

CALGARY ZONE

Forzani and MacPhail Colon Cancer Screening Centre:

Teaching, Research and Wellness Building (TRW)

6th Floor, 3280 Hospital Drive NW

Calgary AB T2N 4N1

Phone 403.944.3800

Website: <http://www.albertahealthservices.ca/ccsc.asp>

SOUTH ZONE

Lethbridge and Area Colorectal Cancer Screening Program

2100 11 Street

Coaldale AB T1M 1L2

Phone 403.345.7009

Fax 403.345.2698

Medicine Hat Colorectal Cancer Screening Clinic

666 5th Street SW

Medicine Hat AB T1A 4H6

Phone 403.529.8016

Fax 403.528.5644

GENERAL RESOURCES

Colorectal Cancer Screening: www.screeningforlife.ca/colorectalcancer

CancerControl Alberta: www.albertahealthservices.ca/8109.asp

Post Polypectomy Surveillance Guidelines available at: www.albertahealthservices.ca/1751.asp

APPENDIX B

OTHER COLORECTAL CANCER SCREENING TESTS

Note: Availability and expertise of the following tests may vary across the province

Flexible sigmoidoscopy: A recent Canadian expert panel on the evidence for the efficacy of flexible sigmoidoscopy in CRC screening concluded that the recently published results from four very large RCTs³²⁻³⁵ provide clear evidence that screening with flexible sigmoidoscopy reduces CRC incidence by about 20% and mortality by about 25% in average risk individuals. Authors of a recent meta-analysis of RCTs of sigmoidoscopy for CRC screening also came to the same conclusion based on the fact that, by intention to screen, sigmoidoscopy reduces incidence of CRC by 18% and mortality due to CRC by 28%, respectively, and by 32% and 50% respectively in those who actually received screening.³⁶ Limitations of flexible sigmoidoscopy include: it views only about a third of the colon and can miss small polyps.³⁷ The risks of complications are very low (.0018% for perforation and .0082% for bleeding).²⁰ Considerations that may affect compliance include: required bowel preparation, time away from work and the test may be uncomfortable.

Colonoscopy: Based on prospective observational studies and case-control studies, the reduction in CRC incidence and mortality in individuals undergoing colonoscopy compared to the general population, ranged from 0.45 to 0.77 for CRC³⁸⁻⁴² incidence and from 0.31 to 0.65 for CRC mortality^{38,43,44} There are concerns that colonoscopy might not be as effective in the right colon as in other segments of the colorectum.^{40,43} Advantages of colonoscopy include: testing is done every 10 years, ability to biopsy and remove polyps, opportunity to diagnose other disease of the colon. The risk of complications reported is approximately 0.5%,²¹ including bleeding, perforation, and cardiopulmonary complications. Considerations that may affect compliance include: required bowel preparation, sedation, time away from work, and the test may be uncomfortable.

CT Colonography: Evidence suggests CT Colonography has comparable sensitivity and specificity to colonoscopy for detecting large polyps but is less accurate than colonoscopy for detecting smaller (<1 cm) polyps according to one meta-analysis.⁴⁵ Considerations that may affect compliance include: exposure to radiation, required bowel preparation, time away from work, and the test may be uncomfortable. A colonoscopy is required if the CT colonography is abnormal.

Double contrast barium enema (DCBE): The effectiveness of DCBE for polyp detection is less than CT colonography. Guidelines and publications reviewed do not support DCBE as a CRC screening test.^{3,23,46}

gFOBT: The gFOBT has lower sensitivity, specificity and test adherence rates when compared to the FIT¹⁹ As of 2014, the gFOBT will be discontinued for screening in Alberta.

Carcinoembryonic antigen (CEA): The specificity of CEA for detecting colorectal cancer is high but the sensitivity is very low. Overall evidence does not support CEA as a screening test.⁴⁷⁻⁵⁰